Skip to main navigation
Telix Pharmaceuticals Limited Logo
  • Overview
  • News
  • Events & Presentations
    • Events
    • Presentations
  • Financials
    • Half-year & Quarterly Results
    • Annual Reports & AGMs
    • ASX Announcements
    • SEC Filings
  • Pipeline
  • Stock
    • Stock Quote & Chart
    • Analyst Coverage
  • Corporate Governance
    • Board & Management
    • Documents & Charters
    • Sustainability
  • Resources
    • Shareholder Information
    • Investor Resources
    • Email Alerts
    • Contact Us

ASX Announcements

Date Title
30 Sep 2026
FDA Fast Track for BiPASS Pre Biopsy Prostate Imaging
25 Sep 2026
Change in substantial holding
25 Sep 2026
Appendix 3Y Change in Director Interest-D Gill
25 Sep 2026
Application for quotation of securities - TLX
22 Sep 2026
Grant of waivers of Listing Rule 7.3.4
21 Sep 2026
Telix + ITM Investor Presentation
21 Sep 2026
Telix and ITM Join Forces to Create Radiopharma Powerhouse
14 Sep 2026
Application for quotation of securities - TLX
14 Sep 2026
FDA Approves Telix Brain Cancer Imaging Drug Pixclara
02 Sep 2026
Telix Completes Enrollment in Phase 3 BiPASS Study
  • Current page 1
  • Page 2
  • Page 3
  • …
  • Next page ›
  • Last page »
Displaying 1 - 10 of 109

Subscribe to our Email Alerts

©2026 Telix Pharmaceuticals Limited.

The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. This website is intended for corporate communication and investor relations purposes only and is not intended as promotion or advertising to any audience in any country worldwide.

Privacy Policy. Terms of Use. Cookies Policy. Forward Looking Statements
  • Twitter
  • LinkedIn
  • Facebook
  • YouTube
Search Investors